Category Archives: Press Releases

Firalis S.A. has launched the EU-funded (EUROSTAR) HeartLinc Program

On 24th of March 2017, the EU-funded (EUROSTAR) HeartLinc program has been launched in Seoul, South Korea, during a first meeting between the Seoul National University Hospital (SNUH), the QuantaMatrix company (Seoul, South Korea) and the Firalis Group (Huningue, France). On 17th of June, the collaboration kicked off together with the European partners of the…
Read more

« Les Echos » article about Firalis collaboration on Rheumatoid Arthritis

« Les Echos », a prestigious financial journal, published an article on our collaboration with HTG Molecular Diagnostics about the development of a theranostic tool to predict response to anti‑TNFα therapies for Rheumatoid Arthritis (RA). Published on September 12th 2016. Click on the link below to view the related press news: « Firalis prédit l'efficacité des thérapies contre…
Read more

Firalis and HTG Agreed to Develop a Theranostic Tool to Predict Response to Anti TNFα Therapies for RA

Firalis and HTG Molecular Diagnostics Announce an Agreement to Develop a Theranostic Tool to Predict Response to Anti‑TNFα Therapies for Rheumatoid Arthritis Firalis SA, a provider of bioanalytical services and biomarker-based products to biopharma, biotechnology companies and academia, a participant of the RABIOPRED EC Funded Project, reached to an agreement with HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM; “HTG”),…
Read more

BIOMARKERS FOR FUTURE MEDICINE

POINT ECO ALSACE, www.pointecoalsace.fr The “Magazine de la chambre de commerce et de l’industrie de la region Alsace”, a prestigious Alsatian industry journal, has reported on FIRALIS, an innovative life sciences company, located in Huningue (France), close to the border of Switzerland and Germany. The company is actively involved in the field of drug safety, of…
Read more